Literature DB >> 20012930

[Liver fibrosis - pathogenesis and novel therapeutic approaches].

F Tacke1, R Weiskirchen.   

Abstract

Chronic liver injury, such as viral hepatitis, alcohol, metabolic syndrome or other toxic damages, leads to an inflammatory response including the infiltration and activation of immune cells and to the proliferation and transdifferentiation of mesenchymal cells within the liver, especially of hepatic stellate cells. These cells produce an excess of extracellular matrix proteins that are deposited in the liver. Hepatic fibrosis may progress to liver cirrhosis and liver failure. This review aims at summarizing the current view on the pathogenic sequence during fibrogenesis highlighting the essential role of cytokines and chemokines. Understanding the complex cellular interactions in liver fibrosis may help to develop novel antifibrotic therapies in the near future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20012930     DOI: 10.1007/s00108-009-2419-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis.

Authors:  Erawan Borkham-Kamphorst; Jens Herrmann; Doris Stoll; Jens Treptau; Axel M Gressner; Ralf Weiskirchen
Journal:  Lab Invest       Date:  2004-06       Impact factor: 5.662

2.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.

Authors:  Frank Tacke; David Alvarez; Theodore J Kaplan; Claudia Jakubzick; Rainer Spanbroek; Jaime Llodra; Alexandre Garin; Jianhua Liu; Matthias Mack; Nico van Rooijen; Sergio A Lira; Andreas J Habenicht; Gwendalyn J Randolph
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  N-acetyl-L-cysteine suppresses TGF-beta signaling at distinct molecular steps: the biochemical and biological efficacy of a multifunctional, antifibrotic drug.

Authors:  Steffen K Meurer; Birgit Lahme; Lidia Tihaa; Ralf Weiskirchen; Axel M Gressner
Journal:  Biochem Pharmacol       Date:  2005-10-01       Impact factor: 5.858

4.  Disruption of intermolecular disulfide bonds in PDGF-BB dimers by N-acetyl-L-cysteine does not prevent PDGF signaling in cultured hepatic stellate cells.

Authors:  Erawan Borkham-Kamphorst; Steffen K Meurer; Axel M Gressner; Ralf Weiskirchen
Journal:  Biochem Biophys Res Commun       Date:  2005-11-02       Impact factor: 3.575

5.  Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis.

Authors:  Paul J Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D Goodman; David Nelson; Robert G Gish; K Rajender Reddy; Robert Reindollar; Maribel Rodriguez-Torres; Sarah Sullivan; Lawrence M Blatt; Sima Faris-Young
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 6.  Mouse models of liver fibrosis.

Authors:  C Weiler-Normann; J Herkel; A W Lohse
Journal:  Z Gastroenterol       Date:  2007-01       Impact factor: 2.000

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 8.  Monocytes and macrophages as cellular targets in liver fibrosis.

Authors:  Felix Heymann; Christian Trautwein; Frank Tacke
Journal:  Inflamm Allergy Drug Targets       Date:  2009-09

9.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.

Authors:  Hermann E Wasmuth; Frank Lammert; Mirko Moreno Zaldivar; Ralf Weiskirchen; Claus Hellerbrand; David Scholten; Marie-Luise Berres; Henning Zimmermann; Konrad L Streetz; Frank Tacke; Sonja Hillebrandt; Petra Schmitz; Hildegard Keppeler; Thomas Berg; Edgar Dahl; Nikolaus Gassler; Scott L Friedman; Christian Trautwein
Journal:  Gastroenterology       Date:  2009-04-01       Impact factor: 22.682

Review 10.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

View more
  4 in total

1.  Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.

Authors:  De Zhao Kong; Ning Liang; Guan Lin Yang; Zhe Zhang; Yue Liu; Jing Li; Xuehan Liu; Shibing Liang; Dimitrinka Nikolova; Janus C Jakobsen; Christian Gluud; Jian Ping Liu
Journal:  Cochrane Database Syst Rev       Date:  2019-11-07

2.  Serum autofluorescence, a potential serum marker for the diagnosis of liver fibrosis in rats.

Authors:  Yu-Tao Zhan; Li Li; Jing Weng; Xin Song; Shao-Qi Yang; Wei An
Journal:  Int J Mol Sci       Date:  2012-09-24       Impact factor: 6.208

3.  Ultrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver Fibrosis.

Authors:  Florian Bert; Jona T Stahmeyer; Siegbert Rossol
Journal:  J Clin Med Res       Date:  2016-07-30

4.  Hepatic stellate cells specific liposomes with the Toll-like receptor 4 shRNA attenuates liver fibrosis.

Authors:  Yuwei Zhang; Yang Li; Tong Mu; Nanwei Tong; Ping Cheng
Journal:  J Cell Mol Med       Date:  2020-12-18       Impact factor: 5.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.